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Introduction {#sec1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that was first isolated in late 2019 from patients with severe respiratory illness in Wuhan, China ([@bib63]). SARS-CoV-2 is related to two other highly pathogenic respiratory viruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 infection results in a clinical syndrome, coronavirus disease 2019 (COVID-19), that can progress to respiratory failure ([@bib24]) and also present with cardiac pathology, gastrointestinal disease, coagulopathy, and a hyperinflammatory syndrome ([@bib11]; [@bib39]; [@bib56]). The elderly, immunocompromised, and those with certain co-morbidities (e.g., obesity, diabetes, and hypertension) are at greatest risk of death from COVID-19 ([@bib62]). Virtually all countries and territories have been affected with more than twenty-seven million infections to date, hundreds of thousands of deaths, and a case-fatality rate estimated at ∼4%. The extensive morbidity, mortality, and destabilizing socioeconomic consequences of COVID-19 highlight the urgent need for deployment of an effective SARS-CoV-2 vaccine to mitigate the severity of infection, curb transmission, end the pandemic, and prevent its return.

The SARS-CoV-2 RNA genome is approximately 30,000 nt in length. The 5′ two-thirds encode nonstructural proteins that enable genome replication and viral RNA synthesis. The remaining one-third encode structural proteins, such as spike (S), envelope, membrane, and nucleoprotein (NP), that form the spherical virion and accessory proteins that regulate cellular responses. The S protein forms homotrimeric spikes on the virion and engages the cell-surface receptor angiotensin-converting enzyme 2 (ACE2) to promote coronavirus entry into human cells ([@bib14]; [@bib35]). The SARS-CoV and SARS-CoV-2 S proteins are cleaved sequentially during the entry process to yield S1 and S2 fragments, followed by further processing of S2 to yield a smaller S2′ protein ([@bib31]). The S1 protein includes the receptor binding domain (RBD), and the S2 protein promotes membrane fusion. The structure of a soluble, stabilized prefusion form of the SARS-CoV-2 S protein was solved by cryoelectron microscopy, revealing considerable similarity to the SARS-CoV S protein ([@bib58]). This form of the S protein is recognized by potently neutralizing monoclonal antibodies ([@bib8]; [@bib47]; [@bib65]) and could serve as a promising vaccine target.

Release of the SARS-CoV-2 genome sequence spurred immediate development of vaccine candidates that principally targeted the viral S protein ([@bib6]). Multiple platforms have been developed to deliver the SARS-CoV-2 S protein, including DNA plasmid, lipid nanoparticle encapsulated mRNA, inactivated virion, and viral-vectored vaccines ([@bib22]). Several vaccines have entered clinical trials to evaluate safety, and some have advanced to trials assessing immunogenicity and efficacy. Most vaccines advanced to human testing without substantive efficacy data in animals ([@bib15]). This circumstance occurred in part because vaccine design and development outpaced the generation of accessible pre-clinical disease models of SARS-CoV-2 infection and pathogenesis.

Adenovirus (Ad)-based vaccines against coronaviruses have been evaluated previously. A single dose of a chimpanzee Ad-vectored vaccine encoding the S protein of MERS-CoV protected mice from infection ([@bib41]), reduced virus shedding, and enhanced survival in camels ([@bib2]) and was safe and immunogenic in humans in a phase 1 clinical trial ([@bib19]). A human Ad-based vaccine expressing a MERS S1-CD40L fusion protein also was protective in mice ([@bib25]). An Ad-based SARS-CoV vaccine expressing the S protein prevented pneumonia in ferrets after challenge and was highly immunogenic in rhesus macaques ([@bib32]). A chimpanzee Ad vector (Y25, a simian Ad-23; [@bib16]) encoding the SARS-CoV-2 S protein (ChAdOx1 nCoV-19) is currently under evaluation in humans as a single intramuscular injection (NCT04324606). In rhesus macaques, this vaccine protects against lung infection and pneumonia, but not against upper respiratory tract infection and virus shedding ([@bib67]).

Here, we develop a different chimpanzee Ad (simian Ad-36)-based SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S) encoding a prefusion stabilized spike (S) protein after introducing two proline substitutions in the S2 subunit ([@bib45]). Intramuscular administration of ChAd-SARS-CoV-2-S induced robust systemic humoral and cell-mediated immune responses. One or two vaccine doses protected against lung infection, inflammation, and pathology after SARS-CoV-2 challenge of mice that transiently express the human ACE2 (hACE2) receptor. Despite the induction of high levels of neutralizing antibody, neither dosing regimen completely protected against SARS-CoV-2 infection, as substantial levels of viral RNA were still detected in the lung. In comparison, a single intranasal dose of ChAd-SARS-CoV-2-S induced high levels of neutralizing antibody and anti-SARS-CoV-2 immunoglobulin A (IgA) and conferred virtually complete protection against infection in both the upper and lower respiratory tracts in mice expressing hACE2 receptor after adenoviral vector delivery or as a transgene. Thus, intranasal immunization of ChAd-SARS-CoV-2-S has the potential to control infection at the site of inoculation, which should prevent both virus-induced disease and transmission.

Results {#sec2}
=======

Chimpanzee Ad-Vectored Vaccine Induces Robust Antibody Responses against SARS-CoV-2 {#sec2.1}
-----------------------------------------------------------------------------------

We constructed two replication-incompetent ChAd vectors based on a simian Ad-36 virus. The ChAd-SARS-CoV-2-S vector encodes the full-length, codon optimized sequence of SARS-CoV-2 S protein as a transgene, including the ectodomain, transmembrane domain, and cytoplasmic domain (GenBank: QJQ84760.1), and is stabilized in prefusion form by two proline substitutions at residues K986 and V987 ([@bib45]; [@bib58]). The ChAd-control has no transgene. The S protein transgene is controlled transcriptionally by a cytomegalovirus promoter. To make the vector replication incompetent and enhance packaging capacity, we replaced the E1A/B genes and introduced a deletion in the E3B gene, respectively ([Figure 1](#fig1){ref-type="fig"} A). To confirm that the S protein was expressed and antigenically intact, we transduced 293T cells and confirmed binding of a panel of 22 neutralizing monoclonal antibodies against the S protein by flow cytometry ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Immunogenicity of ChAd-SARS-CoV-2-S(A) Diagram of transgene cassettes: ChAd-control has no transgene insert; ChAd-SARS-CoV-2-S encodes for SARS-CoV-2 S protein with the two indicated proline mutations.(B) Binding of ChAd-SARS-CoV-2-S transduced 293 cells with anti-S mAbs. (Left) Summary: +, ++, +++, and - indicate \<25%, 25%--50%, \>50%, and no binding, respectively. MFI, mean fluorescence intensity. (Right) Representative flow cytometry histograms of two experiments are shown.(C--F) Four-week-old female BALB/c mice were immunized via intramuscular route with ChAd-control or ChAd-SARS-CoV-2-S and boosted 4 weeks later. Antibody responses in sera of immunized mice at day 21 after priming or boosting were evaluated. An ELISA measured anti-S and RBD IgG and IgA levels (\[D\] and \[E\]), and an FRNT determined neutralization activity (F). Data are pooled from two experiments (n = 15--30).(G and H) Cell-mediated responses were analyzed at day 7 post-booster immunization after re-stimulation with an S protein peptide pool ([Table S1](#mmc1){ref-type="supplementary-material"}). Splenocytes were assayed for IFNγ and granzyme B expression in CD8^+^ T cells and granzyme B only in CD4^+^ T cells by flow cytometry (G). A summary of frequencies and numbers of positive cell populations is shown in (H) (n = 5). Bars indicate median values, and dotted lines are the limit of detection (LOD) of the assays.(I) Spleens were harvested at 7 days post-boost, and SARS-CoV-2 spike-specific IgG^+^ antibody-secreting cell (ASC) frequency was measured by ELISPOT (n = 13).(J) CD8^+^ T cells in the lung were assayed for IFNγ and granzyme B expression by flow cytometry after re-stimulation with an S protein peptide pool (n = 4--5).(K) Lung CD8^+^ T cells also were assayed for expression of CD69 and CD103.(L) Spleens were harvested at 7 days post-boosting, and SARS-CoV-2 spike-specific IgA^+^ ASC frequency was measured by ELISPOT (n = 4--5).(M and N) SARS-CoV-2 S- (M) and RBD-specific (N) IgG and IgA levels in BAL fluid were determined by ELISA (n = 4--5).Bars and columns show median values, and dotted lines indicate the limit of detection (LOD) of the assays. For (D), (F), (H), (I), and (J): Mann-Whitney test: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant. See [Figure S1](#figs1){ref-type="fig"}, [Figure S2](#figs2){ref-type="fig"}, and [S3](#figs3){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

To assess the immunogenicity of ChAd-SARS-CoV-2-S, groups of 4-week-old BALB/c mice were immunized by intramuscular inoculation with 10^10^ virus particles of ChAd-SARS-CoV-2-S or ChAd-control. Some mice received a booster dose 4 weeks later. Serum samples were collected 21 days after primary or booster immunization ([Figure 1](#fig1){ref-type="fig"}C), and IgG responses against purified S and RBD proteins were evaluated by ELISA. Whereas ChAd-SARS-CoV-2-S induced high levels of S- and RBD-specific IgG, low if any levels were detected in the ChAd-control-immunized mice ([Figure 1](#fig1){ref-type="fig"}D). However, intramuscular injection of ChAd-SARS-CoV-2-S failed to induce S- or RBD-specific IgA in serum ([Figure 1](#fig1){ref-type="fig"}E). We next functionally characterized serum antibody responses by assaying neutralization of infectious SARS-CoV-2 using a focus-reduction neutralization test (FRNT) ([@bib9]). As expected, serum from ChAd-control-immunized mice did not inhibit SARS-CoV-2 infection after primary immunization or boosting. In contrast, serum from ChAd-SARS-CoV-2-S-vaccinated animals neutralized SARS-CoV-2 infection, and boosting enhanced this inhibitory activity (geometric mean titers \[GMTs\] of 1/240 and 1/719, respectively; [Figures 1](#fig1){ref-type="fig"}F, [S1](#figs1){ref-type="fig"} A, and S1B).Figure S1ChAd-SARS-CoV-2-S Vaccine Induces Neutralizing Antibodies as Measured by FRNT, Related to [Figure 1](#fig1){ref-type="fig"}Four-week old female BALB/c mice were primed or primed and boosted with ChAd-control or ChAd-SARS-CoV-2-S via intramuscular route. A-B. Serum samples from ChAd-control or ChAd-SARS-CoV-2 vaccinated mice were collected at day 21 after priming (A) or boosting (B) and assayed for neutralizing activity by FRNT. Serum neutralization curves corresponding to individual mice are shown for the indicated vaccines (n = 15-30 per group). Each point represents the mean of two technical replicates. (C). An ELISA measured anti-SARS-CoV-2 NP IgG responses in paired sera obtained 5 days before and 8 days after SARS-CoV-2 challenge of ChAd-control or ChAd-SARS-CoV-2-S mice vaccinated by an intramuscular route (n = 5: ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; paired t test). Dotted lines represent the mean IgG titers from naive sera.

Vaccine-Induced Memory CD8^+^ T Cell and Antigen-Specific B Cell Responses {#sec2.2}
--------------------------------------------------------------------------

Because optimal vaccine immunity is often composed of both humoral and cellular responses ([@bib53]), we measured the levels of SARS-CoV-2-specific CD4^+^ and CD8^+^ T cells after vaccination. 4-week-old BALB/c mice were immunized with ChAd-SARS-CoV-2-S or ChAd-control and boosted 3 weeks later. To assess the vaccine-induced SARS-CoV-2-specific CD4^+^ and CD8^+^ T cell responses, splenocytes were harvested 1 week after boosting and stimulated *ex vivo* with a pool of 253 overlapping 15-mer S peptides ([Table S1](#mmc1){ref-type="supplementary-material"}). Subsequently, quantification of intracellular interferon γ (IFNγ) and granzyme B expression was determined by flow cytometry. After peptide re-stimulation *ex vivo*, splenic CD8^+^ T cells expressed IFNγ and both splenic CD4^+^ and CD8^+^ T cells expressed granzyme B in mice immunized with ChAd-SARS-CoV-2-S, but not the ChAd-control vector ([Figures 1](#fig1){ref-type="fig"}G, 1H, and [S2](#figs2){ref-type="fig"} ). To assess the antigen-specific B cell responses, splenocytes were harvested and subjected to an ELISPOT analysis with S protein. The ChAd-SARS-CoV-2-S vaccine induced S-protein-specific IgG antibody-secreting cells in the spleen, whereas the control vaccine did not ([Figure 1](#fig1){ref-type="fig"}I).Figure S2Gating Strategy for Analyzing T Cell Responses, Related to [Figure 1](#fig1){ref-type="fig"}Four-week old female BALB/c mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S and boosted four weeks later. T cell responses were analyzed in splenocytes at day 7 post-boost. Cells were gated for lymphocytes (FSC-A/SSC-A), singlets (SSC-W/SSC-H), live cells (Aqua^-^), CD45^+^, CD19^-^ followed by CD4^+^ or CD8^+^ cell populations expressing IFNγ or granzyme B.

To assess whether intramuscular vaccination could induce mucosal immune responses in the lungs, mice were immunized with either ChAd-SARS-CoV-2-S or ChAd-control and boosted similarly 4 weeks later. Lungs were harvested 1 week post-boosting, and T cells were analyzed by flow cytometry. Notably, we failed to detect an increase in IFNγ or granzyme B producing CD8^+^ T cells in the lungs of ChAd-SARS-CoV-2-S vaccinated mice after re-stimulation *ex vivo* with a pool of S peptides ([Figure 1](#fig1){ref-type="fig"}J) or CD103^+^CD69^+^CD8^+^ cells that could represent lung-resident memory T cells ([Figure 1](#fig1){ref-type="fig"}K). In the spleen, we also failed to detect antibody-secreting plasma cells producing IgA against the S protein after immunization with ChAd-SARS-CoV-2-S ([Figure 1](#fig1){ref-type="fig"}L). Moreover, we detected low S-specific IgG and no S-specific IgA or RBD-specific IgG or IgA antibodies in bronchoalveolar lavage (BAL) fluid of immunized mice ([Figures 1](#fig1){ref-type="fig"}M and 1N). Thus, although intramuscular vaccination with ChAd-SARS-CoV-2-S produced strong systemic adaptive immune responses against SARS-CoV-2, it induced minimal mucosal immune response.

Intramuscular Immunization with ChAd-SARS-CoV-2-S Vaccine Protects against SARS-CoV-2 Infection in the Lung {#sec2.3}
-----------------------------------------------------------------------------------------------------------

We tested the protective activity of the ChAd vaccine in a recently developed SARS-CoV-2 infection model, wherein BALB/c mice express hACE2 in the lung after intranasal delivery of a vectored human Ad (Hu-Ad5-hACE2; [@bib27]). Endogenous mouse ACE2 does not support viral entry ([@bib35]), and this system enables productive SARS-CoV-2 infection in the mouse lung. 4-week-old BALB/c mice first were immunized via an intramuscular route with ChAd-control or ChAd-SARS-CoV-2-S vaccines. Approximately 30 days later, mice were administered 10^8^ plaque-forming units (PFUs) of Hu-Ad5-hACE2 and anti-Ifnar1 monoclonal antibody (mAb) via intranasal and intraperitoneal routes, respectively. We administered a single dose of anti-Ifnar1 mAb to enhance lung pathogenesis in this model ([@bib27]). We confirmed the absence of cross-immunity between the ChAd and the Hu-Ad5 vector. Serum from ChAd-immunized mice did not neutralize Hu-Ad5 infection ([Figures S3](#figs3){ref-type="fig"} A and S3B).Figure S3Impact of Pre-existing ChAd Immunity on Transduction of Mice with Hu-AdV5-hACE2, Related to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}Four-week old female BALB/c mice were primed or primed and boosted. Serum samples were collected one day prior to Hu-AdV5-hACE2 transduction. Neutralizing activity of Hu-AdV5-hACE2 in the sera from the indicated vaccine groups was determined by FRNT after prime only (A) or prime and boost (B). Each symbol represents a single animal; each point represents two technical repeats and bars indicate the range. A positive control (anti-Hu-Adv5 serum) is included as a frame of reference.

5 days after Hu-Ad5-hACE2 transduction, mice were challenged via intranasal route with 4 × 10^5^ focus-forming units (FFUs) of SARS-CoV-2 ([Figure 2](#fig2){ref-type="fig"} A). At 4 days post-infection (dpi), the peak of viral burden in this model ([@bib27]), mice were euthanized and lungs, spleen, and heart were harvested for viral burden and cytokine analysis. Notably, there was no detectable infectious virus in the lungs of mice immunized with ChAd-SARS-CoV-2-S as determined by plaque assay, whereas high levels were present in mice vaccinated with ChAd-control ([Figure 2](#fig2){ref-type="fig"}B). Using primers that target a sequence within the N gene, we also detected no measurable genomic or subgenomic viral RNA in the heart and spleen and lower levels of viral RNA in the lungs of ChAd-SARS-CoV-2-S-vaccinated animals compared to mice receiving the ChAd-control vector ([Figure 2](#fig2){ref-type="fig"}C). *In situ* hybridization staining for viral RNA in lungs harvested at 4 dpi revealed a substantial decrease of SARS-CoV-2 RNA in pneumocytes of animals immunized with ChAd-SARS-CoV-2-S compared to the ChAd-control ([Figure 2](#fig2){ref-type="fig"}D). A subset of immunized animals was euthanized at 8 dpi, and tissues were harvested for evaluation. At this time point, viral RNA levels again were lower or absent in the lung and spleen of ChAd-SARS-CoV-2-S-immunized mice compared to the control ChAd vector ([Figure 2](#fig2){ref-type="fig"}C). Collectively, these data indicate that a single intramuscular immunization with ChAd-SARS-CoV-2-S results in markedly reduced, but not abrogated, SARS-CoV-2 infection in the lungs of challenged mice.Figure 2Protective Efficacy of Intramuscularly Delivered ChAd-SARS-CoV-2-S against SARS-CoV-2 Infection(A) Scheme of vaccination and challenge. Four-week-old BALB/c female mice were immunized ChAd-control or ChAd-SARS-CoV-2-S. Some mice received a booster dose of the homologous vaccine. On day 35 post-immunization, mice were challenged with SARS-CoV-2 as follows: animals were treated with anti-Ifnar1 mAb and transduced with Hu-AdV5-hACE2 via an intranasal route 1 day later. Five days later, mice were challenged with 4 × 10^5^ focus-forming units (FFUs) of SARS-CoV-2 via the intranasal route.(B and C) Tissues were harvested at 4 and 8 dpi for analysis. Infectious virus in the lung was measured by plaque assay (B), and viral RNA levels were measured in the lung, spleen, and heart at 4 and 8 dpi by qRT-PCR (C; n = 3--7).(D) Viral RNA *in situ* hybridization using SARS-CoV-2 probe (brown color) in the lungs harvested at 4 dpi. Images show low- (top; scale bars, 100 μm) and medium- (middle; scale bars, 100 μm) power magnification with a high-power magnification inset (representative images from n = 3 per group).(E) Fold change in gene expression of indicated cytokines and chemokines from lung homogenates at 4 dpi was determined by qRT-PCR after normalization to *Gapdh* levels and comparison with naive unvaccinated, unchallenged controls (n = 7).(F and G) Mice that received a prime-boost immunization were challenged on day 35 post-booster immunization. Tissues were collected at 4 dpi for analysis. Infectious virus in the lung was determined by plaque assay (F), and viral RNA was measured in the lung, spleen, and heart using qRT-PCR (G; n = 6--7).(B, C, and E--G) Columns show median values, and dotted lines indicate the LOD of the assays. For (B), (C), (E), (F), and (G): Mann-Whitney test: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See [Figure S3](#figs3){ref-type="fig"}.

We next assessed the effect of the vaccine on lung inflammation and disease. Several proinflammatory cytokines and chemokine mRNA levels were lower in the lung tissues of animals immunized with ChAd-SARS-CoV-2-S compared to ChAd-control, including interleukin (*IL*)*-1β*, *CXCL10*, *IFNβ*, *IFNλ*, *IL-6*, and *CXCL11* ([Figure 2](#fig2){ref-type="fig"}E). Moreover, mice immunized with ChAd-control vaccine and challenged with SARS-CoV-2 showed evidence of viral pneumonia characterized by immune cell accumulation in perivascular and alveolar locations, vascular congestion, and interstitial edema. In contrast, animals immunized with ChAd-SARS-CoV-2-S showed a marked attenuation of the inflammatory response in the lung that develops in the ChAd-control-immunized mice ([Figure 3](#fig3){ref-type="fig"} ). Thus, immunization with Ch-Ad-SARS-CoV-2 decreases both viral infection and the consequent lung inflammation and injury associated with SARS-CoV-2 infection.Figure 3Single-Dose Intramuscular Vaccination with ChAd-SARS-CoV-2-S Protects Mice against SARS-CoV-2-Induced Inflammation in the LungFour-week-old female BALB/c mice were immunized with ChAd-control and ChAd-SARS-CoV-2-S and challenged following the scheme described in [Figure 2](#fig2){ref-type="fig"}. Lungs were harvested at 8 dpi. Sections were stained with hematoxylin and eosin and imaged at 40× (left; scale bar, 250 μm), 200× (middle; scale bar, 50 μm), and 400× (right; scale bar, 25 μm) magnifications. Each image is representative of a group of 3 mice.

We then assessed for improved protection using a prime-boost vaccine regimen. BALB/c mice were immunized via an intramuscular route with ChAd-control or ChAd-SARS-CoV-2-S and received a homologous booster dose 4 weeks later. At day 29 post-boost, mice were treated with a single dose of anti-Ifnar1 antibody followed by Hu-Ad5-hACE2 and then challenged with SARS-CoV-2 5 days later. As expected, the prime-boost regimen protected against SARS-CoV-2 challenge with no infectious virus detected in the lungs ([Figure 2](#fig2){ref-type="fig"}F). Although marked reductions of viral RNA in the lung, spleen, and heart were detected at 4 dpi, residual levels of viral RNA still were present, suggesting protection was not complete, even after boosting ([Figure 2](#fig2){ref-type="fig"}G).

A Single Intranasal Immunization with ChAd-SARS-CoV-2-S Induces Protective Immunity against SARS-CoV-2 in Mice Expressing hACE2 Delivered by an Adenoviral Vector {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

Mucosal immunization through the nasopharyngeal route can elicit local immune responses, including secretory IgA antibodies that confer protection at or near the site of inoculation of respiratory pathogens ([@bib43]). To assess the immunogenicity and protective efficacy of mucosal vaccination, 5-week-old BALB/c mice were inoculated via intranasal route with 10^10^ viral particles of ChAd-control or ChAd-SARS-CoV-2-S ([Figure 4](#fig4){ref-type="fig"} A). Serum samples were collected at 4 weeks post-immunization to evaluate humoral immune responses. Intranasal immunization of ChAd-SARS-CoV-2-S, but not ChAd-control, induced high levels of S- and RBD-specific IgG and IgA ([Figures 4](#fig4){ref-type="fig"}B and 4C) and SARS-CoV-2-neutralizing antibodies (GMT of 1/1,574) in serum ([Figures 4](#fig4){ref-type="fig"}D and [S4](#figs4){ref-type="fig"} A). Antibodies from mice immunized with ChAd-SARS-CoV-2-S equivalently neutralized a recombinant, luciferase-expressing variant of SARS-CoV-2 encoding a D614G mutation in the S protein ([Figure S4](#figs4){ref-type="fig"}B); this finding is important, because many circulating viruses contain this substitution, which is associated with greater infectivity in cell culture ([@bib33]). We also assessed the SARS-CoV-2-specific antibody responses in BAL fluid of immunized mice. BAL fluid from ChAd-SARS-CoV-2-S-, but not ChAd-control-, vaccinated mice showed high levels of S- and RBD-specific IgG and IgA antibodies ([Figures 4](#fig4){ref-type="fig"}E and 4F), including those with neutralizing activity ([Figures 4](#fig4){ref-type="fig"}G and [S4](#figs4){ref-type="fig"}C).Figure 4Immune Responses after Intranasal Immunization of ChAd-SARS-CoV-2-S(A) Scheme of experiments. 5-week-old BALB/c female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route.(B--D) Antibody responses in sera of immunized mice at 1 month after priming were evaluated. An ELISA measured SARS-CoV-2 S- and RBD-specific IgG (B) and IgA levels (C), and a FRNT determined neutralization activity (D). Data are pooled from two experiments with n = 10--25 mice per group.(E--J) Mice that received a booster dose were sacrificed 1 week later to evaluate mucosal and cell-mediated immune responses. SARS-CoV-2 S- and RBD-specific IgG (E) and IgA levels (F) in BAL fluid were determined by ELISA. Neutralizing activity of BAL fluid against SARS-CoV-2 was measured by FRNT (G). CD8^+^ T cells in the lung were assayed for IFNγ and granzyme B expression by flow cytometry after re-stimulation with an S protein peptide pool (H). CD8^+^ T cells in the lung also were phenotyped for expression of CD103 and CD69 (I). SARS-CoV-2 spike-specific IgG^+^ and IgA^+^ ASC frequency in the spleen harvested 1 week post-boost was measured by ELISPOT (J). Data for mucosal and cell-mediated responses are pooled from two experiments (E--I: n = 7--9 per group; J: n = 5 per group).(B--J) Bars and columns show median values, and dotted lines indicate the LOD of the assays. Mann-Whitney test: ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See [Figure S4](#figs4){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}.Figure S4Intranasal Inoculation of ChAd-SARS-CoV-2-S Induces Neutralizing Antibodies as Measured by FRNT and Protects against SARS-CoV-2 Replication, Related to [Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}Five-week old female BALB/c mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal inoculation route. Serum samples collected one month after immunization were assayed for neutralizing activity by FRNT. Mice were boosted at day 30 after priming and were sacrificed one week later to evaluate immune responses. (A) Serum samples from ChAd-control or ChAd-SARS-CoV-2-S vaccinated mice were tested for neutralizing activity with SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 (n = 8-10 per group). (B) Serum samples from ChAd-SARS-CoV-2-S vaccinated mice were tested for neutralization of recombinant luciferase-expressing SARS-CoV-2 viruses (wild-type (*left*) and D614G variant (*middle*)). (*Right*) Paired EC~50~ values are indicated (n = 5; n.s. not significant, paired t test). (C) BAL fluid was collected from ChAd-control or ChAd-SARS-CoV-2-S vaccinated mice, and neutralization of SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was measured using a FRNT assay (n = 8-10 per group). Each point represents the mean of two technical replicates. (D) On day 35 post-immunization, mice were challenged via intranasal route with 4 × 10^5^ FFU of SARS-CoV-2 five days after Hu-AdV5-hACE2 transduction and anti-Ifnar1 mAb treatment as described in [Figure 2](#fig2){ref-type="fig"}. Tissues were collected at 4 dpi for viral burden measurements. Genomic RNA (ORF1a) levels were determined in lungs and nasal turbinates (two experiments, n = 6-9; ^∗∗∗∗^p \< 0.0001; Mann-Whitney test). Columns show median values, and dotted lines indicate the LOD of the assays.

To assess T cell responses activated via mucosal immunization, mice were vaccinated via intranasal route with either ChAd-SARS-CoV-2-S or ChAd-control and boosted similarly 4 weeks later. Lungs were harvested 1 week post-boosting, and T cells were analyzed by flow cytometry. Re-stimulation *ex vivo* with a pool of S peptides resulted in a marked increase in IFNγ and granzyme B producing CD8^+^ T cells in the lungs of mice that received the ChAd-SARS-CoV-2-S vaccine ([Figure 4](#fig4){ref-type="fig"}H). Specifically, a population of IFNγ-secreting, antigen-specific CD103^+^CD69^+^CD8^+^ T cells in the lung was identified ([Figure 4](#fig4){ref-type="fig"}I), which is phenotypically consistent with vaccine-induced resident memory T cells ([@bib54]). In the spleen, we detected antibody-secreting plasma cells producing IgA or IgG against the S protein after intranasal immunization with ChAd-SARS-CoV-2-S ([Figure 4](#fig4){ref-type="fig"}J). Of note, we observed an ∼5-fold higher frequency of B cells secreting anti-S IgA than IgG.

We evaluated the protective efficacy of the ChAd vaccine after single-dose intranasal immunization. At day 30 post-vaccination, mice were administered 10^8^ PFUs of Hu-Ad5-hACE2 and anti-Ifnar1 mAb as described above. 5 days later, mice were challenged with 4 × 10^5^ FFUs of SARS-CoV-2. At 4 and 8 dpi, lungs, spleen, heart, nasal turbinates, and nasal washes were harvested and assessed for viral burden. Intranasal delivery of the ChAd-SARS-CoV-2-S vaccine demonstrated remarkable protective efficacy as judged by an absence of infectious virus in the lungs ([Figure 5](#fig5){ref-type="fig"} A) and almost no measurable viral RNA in the lung, spleen, heart, nasal turbinates, or nasal washes, as determined with subgenomic/genomic (N gene) or genomic only (ORF1a gene) TaqMan probes ([Figures 5](#fig5){ref-type="fig"}B and [S4](#figs4){ref-type="fig"}D). The very low viral RNA levels in the lung and nasal turbinates at 4 dpi may reflect the input, non-replicating virus, as similar amounts were measured at this time point in C57BL/6 mice lacking hACE2 receptor expression ([@bib27]). Cytokine and chemokine mRNA levels in lung homogenates also were substantially lower in mice immunized with the ChAd-SARS-CoV-2-S than the ChAd-control vaccine ([Figure 5](#fig5){ref-type="fig"}C), with residual expression likely due to the human Ad vector hACE2 delivery system. Finally, histopathological analysis of lung tissues from animals vaccinated with ChAd-SARS-CoV-2-S by intranasal route and challenged with SARS-CoV-2 showed minimal, if any, perivascular and alveolar infiltrates at 8 dpi compared to the extensive inflammation observed in ChAd-control-vaccinated animals ([Figure 5](#fig5){ref-type="fig"}D).Figure 5Single-Dose Intranasal Immunization with ChAd-SARS-CoV-2-S Protects against SARS-CoV-2 InfectionFive-week-old BALB/c female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route. On day 35 post-immunization, mice were challenged as follows: animals were treated with anti-Ifnar1 mAb and transduced with Hu-AdV5-hACE2 via the intranasal route 1 day later. Five days later, mice were challenged intranasally with 4 × 10^5^ FFUs of SARS-CoV-2.(A--C) Tissues and nasal washes were collected at 4 and 8 dpi for analysis. Infectious virus in the lung was measured by plaque assay (A). Viral RNA levels in the lung, spleen, heart, nasal turbinates, and nasal washes were measured at 4 and 8 dpi by qRT-PCR (B). Fold change in gene expression of indicated cytokines and chemokines was determined by qRT-PCR, normalized to *Gapdh*, and compared to naive controls in lung homogenates at 4 dpi (C; 2 experiments, n = 6--9; median values are shown). Columns show median values, and dotted lines indicate the LOD of the assays.(D) Lungs were harvested at 8 dpi. Sections were stained with hematoxylin and eosin and imaged at 40× (left; scale bar, 250 μm), 200× (middle; scale bar, 50 μm), and 400× (right; scale bar, 25 μm) magnifications. Each image is representative of a group of 3 mice.(E) An ELISA measured anti-SARS-CoV-2 NP IgM (left) and IgG (right) antibody responses in paired sera obtained 5 days before and 8 days after SARS-CoV-2 challenge of ChAd-control or ChAd-SARS-CoV-2-S mice vaccinated by an intranasal route (n = 6). Dotted lines represent the LOD of the assay. Dashed lines indicate the mark for a 4-fold increase of pre-boost IgM and IgG levels.For (A)--(C): Mann-Whitney test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; for (E): ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001; paired t test. See [Figures S4](#figs4){ref-type="fig"} and [S5](#figs5){ref-type="fig"}.

To begin to determine whether sterilizing immunity might be achieved with intranasal delivery of ChAd-SARS-CoV-2-S, we measured anti-NP antibodies at 8 dpi and compared them to responses from 5 days before SARS-CoV-2 infection. Because the NP gene is absent from the vaccine vector, induction of humoral immune responses against NP after SARS-CoV-2 exposure ([@bib44]) suggests viral protein translation and active infection. After SARS-CoV-2 challenge, anti-NP antibody responses were detected in ChAd-control mice vaccinated by an intranasal route or ChAd-control and ChAd-SARS-CoV-2-S mice vaccinated by an intramuscular route ([Figures 5](#fig5){ref-type="fig"}E and [S1](#figs1){ref-type="fig"}C). Remarkably, none of the mice immunized with ChAd-SARS-CoV-2-S via an intranasal route showed significant increases in anti-NP antibody responses after SARS-CoV-2 infection ([Figures 5](#fig5){ref-type="fig"}E and [S5](#figs5){ref-type="fig"} ). Combined with our virological analyses, these data suggest that a single intranasal immunization of ChAd-SARS-CoV-2-S induces robust mucosal immunity, which prevents SARS-CoV-2 infection in the upper and lower respiratory tracts of mice expressing the hACE2 receptor.Figure S5SARS-CoV-2 NP-Specific IgM and IgG Antibody Responses following SARS-CoV-2 Challenge, Related to [Figure 5](#fig5){ref-type="fig"}Five-week-old BALB/c female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route. One month later, mice were transduced with Hu-AdV5-ACE2 and challenged with SARS-CoV-2 as described in [Figure 5](#fig5){ref-type="fig"}. An ELISA measured anti-SARS-CoV-2 NP IgM and IgG responses in paired sera obtained 5 days before and 8 days after SARS-CoV-2 challenge. Serum ELISA curves corresponding to individual mice are shown for the indicated vaccines or control naive BALB/c mice (n = 6 per group).

A Single Intranasal Immunization with ChAd-SARS-CoV-2-S Prevents SARS-CoV-2 Infection in the Upper and Lower Respiratory Tracts of hACE2 Transgenic Mice {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Recently, we and others established a more stringent, lethal SARS-CoV-2 challenge model ([@bib48]; [@bib57]) in transgenic C57BL/6 mice that have eight inserted copies of the *hACE2* gene driven by the K18 cytokeratin epithelial cell promoter ([@bib40]). Within 1 week of SARS-CoV-2 inoculation by an intranasal route, K18-hACE2 mice develop severe lung infection and inflammation, immune cell infiltration, and compromised respiratory function that results in death. As an independent test of the efficacy of intranasal administration of ChAd-SARS-CoV-2-S, we assessed its immunogenicity and protective efficacy in K18-hACE2 mice.

4-week-old K18-hACE2 mice were inoculated via an intranasal route with 10^10^ viral particles of ChAd-control or ChAd-SARS-CoV-2-S ([Figure 6](#fig6){ref-type="fig"} A). Serum samples were collected at 4 weeks post-immunization, and humoral immune responses were evaluated. Intranasal immunization of ChAd-SARS-CoV-2-S, but not ChAd-control, induced high levels of S- and RBD-specific IgG and IgA ([Figures 6](#fig6){ref-type="fig"}B and 6C) and neutralizing antibodies (GMT of 1/1,424) in serum ([Figures 6](#fig6){ref-type="fig"}D and [S6](#figs6){ref-type="fig"} ). At day 30 post-vaccination, K18-hACE2 mice were challenged via an intranasal route with 10^3^ FFUs of SARS-CoV-2. At 4 dpi, lungs, spleen, heart, nasal turbinates, and nasal washes were harvested and assessed for viral burden. Similar to that seen in BALB/c mice transiently expressing hACE2, intranasal immunization of ChAd-SARS-CoV-2-S conferred remarkable protection as judged by an absence of infectious virus in the lungs ([Figure 6](#fig6){ref-type="fig"}E), no measurable viral subgenomic/genomic RNA in the lungs or hearts, and very low levels of viral RNA in the nasal turbinates or washes ([Figure 6](#fig6){ref-type="fig"}F). Consistent with these results, after SARS-CoV-2 challenge, we observed no induction of cytokine and chemokine mRNA (e.g., CCL2, CXCL1, CXCL10, CXCL11, IL-6, IFNβ, and IFNλ) in the lung homogenates of ChAd-SARS-CoV-2-S-immunized compared to naive mice, whereas ChAd-control-vaccinated mice sustained high levels ([Figure 6](#fig6){ref-type="fig"}G). Collectively, these data suggest that a single intranasal immunization of ChAd-SARS-CoV-2-S induces robust systemic and mucosal immunity that blocks SARS-CoV-2 infection in the upper and lower respiratory tract of highly susceptible K18-hACE2 transgenic mice.Figure 6Immunogenicity and Protective Efficacy after Intranasal Immunization of ChAd-SARS-CoV-2-S in K18-hACE2 Mice(A) Scheme of experiments. Four-week-old K18-hACE2 female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route.(B--D) Antibody responses in sera of immunized mice at 4 weeks after priming were evaluated. An ELISA measured SARS-CoV-2 S-and RBD-specific IgG (B) and IgA levels (C), and a FRNT determined neutralization activity (D; n = 7).(E--G) At 1 month post-immunization, mice were challenged with 10^3^ FFUs of SARS-CoV-2. Tissues and nasal washes were harvested at 4 dpi. Infectious virus in lungs was measured using plaque assay (E). Viral RNA levels in the lung, spleen, heart, nasal turbinates, and nasal washes were measured at 4 dpi by qRT-PCR (F). Fold change in gene expression of indicated cytokines and chemokines was determined by qRT-PCR, normalized to *Gapdh*, and compared to naive controls in lung homogenates at 4 dpi (G; n = 7). Boxes indicate median values, and dotted lines indicate the LOD of the assays.For (B)--(G): Mann-Whitney test: ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See [Figure S6](#figs6){ref-type="fig"}.Figure S6Intranasal Inoculation of ChAd-SARS-CoV-2-S Induces Neutralizing Antibodies in K18-hACE2 Mice, Related to [Figure 6](#fig6){ref-type="fig"}Four-week old female K18-hACE2 mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal inoculation route. Serum samples collected four weeks after immunization were assayed for neutralizing activity by FRNT (n = 7 per group). Each point represents the mean of two technical replicates.

Discussion {#sec3}
==========

In this study, we evaluated intramuscular and intranasal administration of a replication-incompetent ChAd vector as a vaccine platform for SARS-CoV-2. Single-dose immunization of a stabilized S-protein-based vaccine via an intramuscular route induced S- and RBD-specific binding as well as neutralizing antibodies. Vaccination with one or two doses protected mice expressing human ACE2 against SARS-CoV-2 challenge, as evidenced by an absence of infectious virus in the lungs and substantially reduced viral RNA levels in lungs and other organs. Mice immunized with ChAd-SARS-CoV-2-S also showed markedly reduced if not absent lung pathology, lung inflammation, and evidence of pneumonia compared to the control ChAd vaccine. However, intramuscular vaccination of ChAd-SARS-CoV-2-S did not induce IgA responses or confer sterilizing immunity, as evidenced by detectable viral RNA levels in the lung and induction of anti-NP antibody responses. Mice immunized with a single dose of the ChAd-SARS-CoV-2-S via an intranasal route also were protected against SARS-CoV-2 challenge. Intranasal vaccination, however, generated robust IgA and neutralizing antibody responses that likely protected against both upper and lower respiratory tract SARS-CoV-2 infection and inhibited infection of both wild-type and D614G variant viruses. The very low levels of genomic viral RNA in upper airway tissues and absence of serological response to NP in the context of challenge strongly suggests that at least some animals receiving a single intranasal dose of ChAd-SARS-CoV-2-S likely achieved sterilizing immunity.

Although several vaccine candidates (e.g., lipid-encapsulated mRNA, DNA, inactivated, and viral vectored) rapidly advanced to human clinical trials in an expedited effort to control the pandemic ([@bib4]), few studies have demonstrated efficacy in pre-clinical models. Rhesus macaques immunized with two or three doses of a DNA plasmid vaccine encoding full-length SARS-CoV-2 S protein induced neutralizing antibody in sera and reduced viral burden in BAL and nasal mucosa fluids ([@bib59]). Three immunizations over 2 weeks with purified, inactivated SARS-CoV-2 induced neutralizing antibodies and, depending on the dose administered, provided partial or complete protection against infection and viral pneumonia in rhesus macaques ([@bib21]). Finally, two intramuscular doses of a lipid-encapsulated, mRNA-based vaccine against S protected against SARS-CoV-2 infection in nasal swabs and BAL fluid of rhesus macaques ([@bib12]). One limitation of these challenge models is that rhesus macaques develop lower viral burden and mild interstitial pneumonia after SARS-CoV-2 infection compared to some humans and other non-human primate species ([@bib10]; [@bib42]). Our study in hACE2-expressing mice shows that a single intramuscular or intranasal dose of ChAd-SARS-CoV-2-S vaccine confers substantial and possibly complete protection against viral replication, inflammation, and lung disease.

Our approach supports the use of non-human Ad-vectored vaccines against emerging RNA viruses, including SARS-CoV-2. Previously, we showed the efficacy of single-dose or two-dose regimens of a gorilla Ad encoding the prM-E genes of Zika virus (ZIKV) in several mouse challenge models, including in the context of pregnancy ([@bib26]). Others have evaluated ChAd or rhesus macaque Ad vaccine candidates against ZIKV and shown efficacy in mice and non-human primates ([@bib1]; [@bib37]). A different ChAd encoding the wild-type SARS-CoV-2 S protein (ChAdOx1) is currently in clinical trials in humans (NCT04324606) and a phase 1/2 trial showed neutralizing antibody responses against SARS-CoV-2 in 91% and 100% participants after one- or two-dose immunization regimens ([@bib20]). Studies in rhesus macaques with ChAdOx1 suggest that a single intramuscular dose protects against infection in the lung, but not in the upper respiratory tract ([@bib67]). None of the vaccines evaluated against SARS-CoV-2 has shown evidence of immune enhancement in any pre-clinical or clinical study, which has been a theoretical risk based on studies with other human and animal coronaviruses ([@bib13]; [@bib15]). Indeed, and in contrast to data with SARS-CoV vaccines or antibodies ([@bib5]; [@bib36]; [@bib55]), we did not observe enhanced infection, immunopathology, or disease in animals immunized with ChAd encoding SARS-CoV-2 S proteins or administered passively transferred monoclonal antibodies ([@bib3]; [@bib27]).

ChAd-SARS-CoV-2-S induced SARS-CoV-2-specific CD8^+^ T cell responses, including a high percentage and number of IFNγ- and granzyme-expressing cells after *ex vivo* S protein peptide re-stimulation. The induction of CD8^+^ T cell responses by the ChAd-SARS-CoV-2-S vaccine is consistent with reports with other simian Ad vectors ([@bib17]; [@bib30]; [@bib49]). ChAd vaccine vectors not only overcome issues of pre-existing immunity against human adenoviruses but also have immunological advantages because they do not induce exhausted T cell responses ([@bib46]).

A single intranasal dose of ChAd-SARS-CoV-2-S conferred superior immunity against SARS-CoV-2 challenge, more so than one or two intramuscular immunizations of the same vaccine and dose ([Figure 7](#fig7){ref-type="fig"} ). Additionally, one intranasal dose of ChAd-SARS-CoV-2-S prevented upper and lower respiratory tract infection and inflammation by SARS-CoV-2 in highly susceptible K18-hACE2 transgenic mice ([@bib48]; [@bib57]). Given that the serum-neutralizing antibody responses were relatively comparable, we hypothesize the greater protection observed after intranasal delivery was because of the mucosal immune responses generated. Indeed, high levels of anti-SARS-CoV-2 IgA were detected in serum and lung, and B cells secreting IgA were detected in the spleen only in mice vaccinated via an intranasal route. Moreover, intranasal, but not intramuscular, vaccination induced SARS-CoV-2-specific CD8^+^ T cells in the lung, including CD103^+^CD69^+^ cells, which are likely of a resident memory phenotype. Future antibody passive transfer and T cell depletion studies can assess the relative contribution of each immune arm to protection and establish more precisely the mechanistic basis for the enhanced protection conferred by intranasal delivery of ChAd-SARS-CoV-2-S.Figure 7Comparison of Immunogenicity of Single-Dose Administration of ChAd-SARS-CoV-2-S by Intramuscular and Intranasal Delivery Routes(Upper panel) After intramuscular inoculation, ChAd-SARS-CoV-2 vaccine transduces antigen-presenting cells (APCs) at the site of injection in muscle tissues. APCs migrate to lymphoid tissues where antigen-specific CD8^+^T cells become activated, proliferate, and produce IFNγ and granzyme B. Antigen-specific B cells proliferate, some of which become plasmablasts and plasma cells that secrete anti-S IgG. After SARS-CoV-2 challenge, activated CD8^+^ T cells migrate to the lungs to control infection and anti-S IgG neutralizes virus particles. Intramuscular vaccination protects against lower, but not upper, airway infection and does not efficiently induce mucosal immunity. (Lower panel) After intranasal inoculation, ChAd-SARS-CoV-2 transduces APCs in the upper respiratory tract. APCs then migrate to bronchial- or mucosal-associated lymphoid tissues to present antigens to lymphocytes, including B and T cells. After SARS-CoV-2 challenge, activated CD8^+^ T cells migrate to the lungs, secrete cytokines, and attack virus-infected cells. Some CD8^+^ T cells likely adopt a tissue-resident memory phenotype (CD103^+^ CD69^+^), enabling them to reside in the lung (or upper airway) and respond more rapidly after re-encountering cognate antigen (SARS-CoV-2 S peptides). The activated B cell becomes responsive after intranasal vaccination produces cells that secrete anti-SARS-CoV-2-S IgG or IgA, the latter of which neutralizes virus within the upper and lower respiratory tracts. The mucosal immunity generated by intranasal inoculation of ChAd-SARS-CoV-2 likely controls infection at the point of initiation in the upper respiratory tract.

To our knowledge, none of the SARS-CoV-2 vaccine platforms currently in clinical trials use an intranasal delivery approach. There has been great interest in using intranasal delivery for influenza A virus vaccines because of their ability to elicit local humoral and cellular immune responses ([@bib7]). Indeed, sterilizing immunity to influenza A virus re-infection requires local adaptive immune responses in the lung, which is optimally induced by intranasal and not intramuscular inoculation ([@bib18]; [@bib34]). Although there are concerns with administering live-attenuated viral vaccines via an intranasal route, subunit-based or replication-incompetent vectored vaccines are promising for generating mucosal immunity in a safer manner, especially given advances in formulation ([@bib61]).

Limitations of Study {#sec3.1}
--------------------

Although a single intranasal administration of ChAd-SARS-CoV-2-S protected against SARS-CoV-2 replication in lungs, we note some limitations in our study. We performed most challenge studies in mice transduced with hACE2 using a human Ad5 vector, which could be complicated by vector immunity. Notwithstanding this possibility, we confirmed an absence of heterologous neutralizing serum antibody induced by one or two doses of ChAd vector against the Hu-Ad5 and, more importantly, detected high levels of SARS-CoV-2 infection in the ChAd-control-vaccinated mice after challenge. Moreover, we reproduced the level of protection by ChAd-SARS-CoV-2-S in K18-hACE2 transgenic mice. Immunization and challenge studies with hamsters and non-human primates are planned to confirm the extent of protective mucosal immunity conferred by ChAd-SARS-CoV-2-S in mice and expand upon our understanding of how the route of inoculation impacts vaccine-mediated protection. Moreover, studies in humans are needed to assess for cross-immunity between the ChAd vector (simian Ad-36) and adenoviruses circulating in humans. Although we expect this will be much less than that observed with Hu-Ad5 vaccine vectors ([@bib64]), low levels of pre-existing immunity against simian adenoviruses could affect vaccine efficacy in selected populations with non-human primate exposures (e.g., zoo workers, veterinarians, and laboratory workers at primate centers). Finally, studies must be conducted to monitor immune responses over time after intranasal vaccination with ChAd-SARS-CoV-2-S to establish the durability of the protective response.

In summary, our studies establish that immunization with ChAd-SARS-CoV-2-S induces both neutralizing antibody and antigen-specific CD8^+^ T cell responses. Although a single intramuscular immunization of ChAd-SARS-CoV-2-S confers protection against SARS-CoV-2 infection and inflammation in the lungs, intranasal delivery of ChAd-SARS-CoV-2-S induces mucosal immunity, provides superior protection, and possibly promotes sterilizing immunity, at least in mice that transiently or stably express the hACE2 receptor. We suggest that intranasal delivery of ChAd-SARS-CoV-2-S is a promising platform for preventing SARS-CoV-2 infection, disease, and upper airway transmission and thus warrants clinical evaluation in humans.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**SARS2-01, anti-SARS-CoV-2 mAbThis paperN/ASARS2-02, anti-SARS-CoV-2 mAbThis paperN/ASARS2-07, anti-SARS-CoV-2 mAbThis paperN/ASARS2-11, anti-SARS-CoV-2 mAbThis paperN/ASARS2-12, anti-SARS-CoV-2 mAbThis paperN/ASARS2-16, anti-SARS-CoV-2 mAbThis paperN/ASARS2-18, anti-SARS-CoV-2 mAbThis paperN/ASARS2-20, anti-SARS-CoV-2 mAbThis paperN/ASARS2-21, anti-SARS-CoV-2 mAbThis paperN/ASARS2-22, anti-SARS-CoV-2 mAbThis paperN/ASARS2-23, anti-SARS-CoV-2 mAbThis paperN/ASARS2-29, anti-SARS-CoV-2 mAbThis paperN/ASARS2-31, anti-SARS-CoV-2 mAbThis paperN/ASARS2-32, anti-SARS-CoV-2 mAbThis paperN/ASARS2-34, anti-SARS-CoV-2 mAbThis paperN/ASARS2-38, anti-SARS-CoV-2 mAbThis paperN/ASARS2-39, anti-SARS-CoV-2 mAbThis paperN/ASARS2-50, anti-SARS-CoV-2 mAbThis paperN/ASARS2-55, anti-SARS-CoV-2 mAbThis paperN/ASARS2-58, anti-SARS-CoV-2 mAbThis paperN/ASARS2-66, anti-SARS-CoV-2 mAbThis paperN/ASARS2-71, anti-SARS-CoV-2 mAbThis paperN/AGoat anti-mouse IgG, human ads-HRPSouthern BiotechCat \# 1030-05; RRID: [AB_2619742](nif-antibody:AB_2619742){#intref0020}CR3022, anti-SARS-CoV-2 mAb[@bib60]N/AGoat anti-mouse IgG, human ads-BIOTSouthern BiotechCat \# 1030-08; RRID: [AB_2794296](nif-antibody:AB_2794296){#intref0025}Goat anti-mouse IgA-BIOTSouthern BiotechCat \# 1040-08; RRID: [AB_2794374](nif-antibody:AB_2794374){#intref0030}Goat anti-mouse IgM-BIOTSouthern BiotechCat \# 1021-08; RRID: [AB_2794242](nif-antibody:AB_2794242){#intref0035}HRP-conjugated goat anti-human IgGThermo Fisher62-8420; RRID: [AB_2533962](nif-antibody:AB_2533962){#intref0040}MAR1-5A3, anti-Ifnar1 mAbLeincoI-401; RRID: [AB_2491621](nif-antibody:AB_2491621){#intref0045}Anti-HuAdV5-hexon antibodyNovus BiologicalsCat \# NB600413; RRID: [AB_10002549](nif-antibody:AB_10002549){#intref0050}Streptavidin-HRPVector LaboratoriesCat \# SA-5004; RRID: [AB_2336509](nif-antibody:AB_2336509){#intref0055}Peroxidase StreptavidinJackson ImmunoResearchCat \# 016-030-084; RRID: [AB_2337238](nif-antibody:AB_2337238){#intref0060}Alexa Fluor 647 anti-IFNγBD BioScienceCat \# 557735; RRID: [AB_396843](nif-antibody:AB_396843){#intref0065}Anti-mouse CD16/32eBioSceinceCat \# 14-0161-85; RRID: [AB_467134](nif-antibody:AB_467134){#intref0070}BUV395 anti-CD45BD BioSciencesCat \# 564279; RRID: [AB_2651134](nif-antibody:AB_2651134){#intref0075}PE anti-CD44BioLegendCat \# 103024; RRID: [AB_493687](nif-antibody:AB_493687){#intref0080}PerCP/Cy5.5 anti-CD8bBioLegendCat \# 126610; RRID: [AB_2260149](nif-antibody:AB_2260149){#intref0085}APC/Cy7 anti-CD19BioLegendCat \# 115530; RRID: [AB_830707](nif-antibody:AB_830707){#intref0090}Fixable Aqua dead cell stainInvitrogenCat \# L34965;BV 605 anti-TNFαBioLegendCat \# 506329; RRID:[AB_11123912](nif-antibody:AB_11123912){#intref0095}BV421 anti-CD4BioLegendCat \# 100437; RRID: [AB_10900241](nif-antibody:AB_10900241){#intref0100}FITC anti-CD103BioLegendCat \# 121419; RRID: [AB_10709438](nif-antibody:AB_10709438){#intref0105}BV711 anti-CD69BioLegendCat \# 104537; RRID: [AB_2566120](nif-antibody:AB_2566120){#intref0110}PE anti-granzyme BInvitrogenCat \# GRB04; RRID: [AB_2536538](nif-antibody:AB_2536538){#intref0115}PE/Cy5 anti-CD4BioLegendCat \# 100409; RRID: [AB_312694](nif-antibody:AB_312694){#intref0120}**Virus and bacterial Strains**SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020)CDC/BEI ResourcesNR52281ChAd-SARS-CoV-2-SThis paperN/AChAd-ControlThis paperN/AAdV-hACE2This paperN/A*E. coli* strain BJ5183AgilentCat \# 200154*BL21(DE3)-RIL E. coli*InvitrogenCat \# C601003**Experimental Models: Cell Lines**Vero CCL-81ATCCCCL-81; RRID: CVCL_0059Vero E6ATCCCRL-1586; RRID: CVCL_0574HEK293ATCCCRL-1573; RRID: CVCL_0045HEK293TATCCCRL-3216; RRID: CVCL_0063Expi293F cellsInvitrogenCat \# A14527**Experimental Models: Organisms/Strains**Mouse: C57BL/6JJackson LaboratoryCat\#000664; RRID: IMSR_JAX:000664Mouse: BALB/cJackson LaboratoryCat\#000651; RRID: IMSR_JAX:000651Mouse: B6.Cg-Tg(K18-ACE2)2Prlmn/JJackson LaboratoryCat\# 034860; RRID: IMSR_JAX:03486**Oligonucleotides**SARS-CoV-2 N F: 5′-ATGCTGCAATCGTGCTACAA-3′This paperN/ASARS-CoV-2 N R: 5′-GACTGCCGCCTCTGCTC-3′This paperN/ASARS-CoV-2 N Probe: 5′-/56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/-3′This paperN/ASARS-CoV-2 ORF1a F: 5′- TTCAGTTGACTTCGCAGTGG −3′This paperN/ASARS-CoV-2 ORF1a R: 5′- GGACGGGTTTGAGTTTTTCA −3′This paperN/ASARS-CoV-2 ORF1a Probe: 5′-/56-FAM/AACTAACAT/ZEN/CTTTGGCACTGTTT/3IABkFQThis paperN/ASARS-CoV-2 RNA ISH probe (S gene)Advanced Cell DiagnosticsCat\# 4848561*Gapdh* TaqMan Primer/Probe setIDTMm.PT.39a.1*Ifng* TaqMan Primer/Probe setIDTMm.PT.58.41769240*Il6* TaqMan Primer/Probe setIDTMm.PT.58.10005566*Il1b* TaqMan Primer/Probe setIDTMm.PT.58.41616450*Tnfa* TaqMan Primer/Probe setIDTMm.PT.58.12575861*Cxcl10* TaqMan Primer/Probe setIDTMm.PT.58.43575827*Ccl2* TaqMan Primer/Probe setIDTMm.PT.58.42151692*Ccl5* TaqMan Primer/Probe setIDTMm.PT.58.43548565*Cxcl11* TaqMan Primer/Probe setIDTMm.PT.58.10773148.g*Ifnb* TaqMan Primer/Probe setIDTMm.PT.58.30132453.g*Ifnl*(2/3*)* TaqMan Primer/Probe setThermo FisherMm04204156_gH**Software and Algorithms**FlowJoFlowJo, LLCv10GraphPad PrismGraphPadv 8.2.1Biorenderbiorender.comN/A**Recombinant DNA**pABVec6W[@bib66]N/ASimian Ad36 vectorPenn Vector Core[@bib50]pSAd36-SThis paperN/ApAd36-ControlThis paperN/ApAd-hACE2This paperN/AAdEasy AdV vector systemAgilent technologiesCat\# 240009PCR-II topoInvitrogenCat\# 451245

Resource Availablity {#sec4.2}
--------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael S. Diamond (<diamond@wusm.wustl.edu>).

### Materials Availability {#sec4.2.2}

All requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author. This includes mice, antibodies, viruses, vaccines, proteins, and peptides. All reagents will be made available on request after completion of a Materials Transfer Agreement.

### Data and Code Availability {#sec4.2.3}

All data supporting the findings of this study are available within the paper and are available from the corresponding author upon request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Viruses and cells {#sec4.3.1}

Vero E6 (CRL-1586, American Type Culture Collection (ATCC), Vero CCL81 (ATCC), and HEK293 cells were cultured at 37°C in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1X non-essential amino acids, and 100 U/ml of penicillin--streptomycin

SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the Centers for Disease Control and Prevention (a gift from Natalie Thornburg). The virus was passaged once in Vero CCL81 cells and titrated by focus-forming assay (FFA) on Vero E6 cells. The recombinant luciferase-expressing full-length SARS-CoV-2 reporter virus (2019 n-CoV/USA_WA1/2020 strain) has been reported previously ([@bib65]), and the D614G variant will be described elsewhere (R. Baric, manuscript in preparation). All work with infectious SARS-CoV-2 was performed in Institutional Biosafety Committee approved BSL3 and A-BSL3 facilities using appropriate positive pressure air respirators and protective equipment.

### Mouse experiments {#sec4.3.2}

Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (Assurance number A3381-01). Virus inoculations were performed under anesthesia that was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.

Female BALB/c (catalog 000651) and K18-hACE2 C57BL/6 (catalog 034860) mice were purchased from The Jackson Laboratory. Four to five-week-old animals were immunized with 10^10^ viral particles (vp) of ChAdV-empty or ChAd-SARS-CoV-2-S in 50 μl PBS via intramuscular injection in the hind leg or via intranasal inoculation. Subsets of immunized animals were boosted four weeks after primary immunization using the same route used for primary immunization. Vaccinated BALB/c mice (10 to 11-week-old) were given a single intraperitoneal injection of 2 mg of anti-Ifnar1 mAb (MAR1-5A3 ([@bib52]), Leinco) one day before intranasal administration of 10^8^ PFU of Hu-AdV5-hACE2. Five days after Hu-AdV5 transduction, mice were inoculated with 4 × 10^5^ FFU of SARS-CoV-2 by the intranasal route. K18-hACE2 mice were challenged on day 30 after immunization with 10^3^ PFU of SARS-CoV-2 via an intranasal route. Animals were euthanized at 4 or 8 dpi, and tissues were harvested for virological, immunological, and pathological analyses.

Method Details {#sec4.4}
--------------

### Construction of chimpanzee adenovirus vectors {#sec4.4.1}

Simian Ad36 vector (ChAd) ([@bib50]) was obtained from the Penn Vector Core of the University of Pennsylvania. The ChAd genome was engineered with deletions in the E1 and E3B region (GenBank: [FJ025917.1](ncbi-n:FJ025917.1){#intref0130}; nucleotides 455-3026 and 30072-31869, respectively). A modified human cytomegalovirus major immediate early promoter sequence was incorporated in place of the E1 gene in reverse orientation on the complementary DNA strand. CMV modification included an addition of two copies of the tet operator 2 (TetO2) sequence ([@bib29]) inserted in tandem (5′-TCT CTA TCA CTG ATA GGG AGA TCT CTA TCA CTG ATA GG GA-3′) between the TATA box and the mRNA start (GenBank: MN920393, nucleotides 174211-174212). SARS-CoV-2 S (GenBank MN908947.3; and two proline substitutions at residues K986 and V987 that stabilize the prefusion form of S ([@bib45]; [@bib58])) were cloned into a unique *Pme*I site under the CMV-tetO2 promoter control in pSAd36 genomic plasmid to generate pSAd36-S. In parallel, a pSAd36-control carrying an empty CMV-tetO2 cassette with no transgene also was generated. The pSAd36-S and pSAd-control plasmids were linearized with *Pac*I restriction enzyme to liberate viral genomes for transfection into T-Rex 293-HEK cells (Invitrogen). The rescued replication-incompetent ChAd-SARS-CoV-2-S and ChAd-Control vectors were scaled up in 293 cells and purified by CsCl density-gradient ultracentrifugation. Viral particle concentration in each vector preparation was determined by spectrophotometry at 260 nm as described ([@bib38]).

### Construction of a human adenovirus vector expressing human ACE2 {#sec4.4.2}

Codon-optimized hACE2 sequences were cloned into the shuttle vector (pShuttle-CMV, Addgene 240007) to generate pShuttle-hACE2. pShuttle-hACE2 was linearized with *Pme*I and subsequently cotransformed with the HuAdv5 backbone plasmid (pAdEasy-1 vector; Addgene 240005) into *E. coli* strain BJ5183 to generate pAdV5-ACE2 by homologous recombination as described ([@bib28]). The pAdEasy-1 plasmid containing the HuAdV5 genome has deletions in E1 and E3 genes. hACE2 is under transcriptional control of a cytomegalovirus promotor and is flanked at its 3′ end by a SV40 polyadenylation signal. The pAd-hACE2 was linearized with *Pac*I restriction enzyme before transfection into T-Rex 293 HEK cells (Invitrogen) to generate HuAdv5-hACE2. Recombinant HuAdv5-hACE2 was produced in 293-HEK cells and purified by CsCl density-gradient ultracentrifugation. The viral titer was determined by plaque assay in 293-HEK cells.

### *In situ* RNA hybridization and histology {#sec4.4.3}

RNA *in situ* hybridization was performed using RNAscope 2.5 HD (Brown) (Advanced Cell Diagnostics) according to the manufacturer's instructions. Left lung tissues were collected at necropsy, inflated with 10% neutral buffered formalin (NBF), and thereafter immersion fixed in 10% NBF for seven days before processing. Paraffin-embedded lung sections were deparaffinized by incubating at 60°C for 1 h, and endogenous peroxidases were quenched with H~2~O~2~ for 10 min at room temperature. Slides were boiled for 15 min in RNAscope Target Retrieval Reagents and incubated for 30 min in RNAscope Protease Plus reagent prior to SARS-CoV2 RNA probe (Advanced Cell Diagnostics 848561) hybridization and signal amplification. Sections were counterstained with Gill's hematoxylin and visualized by brightfield microscopy. Some lung sections were processed for histology after hematoxylin and eosin staining.

### SARS-CoV-2 neutralization assays {#sec4.4.4}

Heat-inactivated serum samples were diluted serially and incubated with 10^2^ FFU of SARS-CoV-2 for 1 h at 37°C. The virus-serum mixtures were added to Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were incubated for 30 h before fixation using 4% PFA in PBS for 1 h at room temperature. Cells were washed and then sequentially incubated with anti-SARS-CoV-2 CR3022 antibody ([@bib60]) (1 μg/mL) and a HRP-conjugated goat anti-human IgG (Sigma) in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA. TrueBlue peroxidase substrate (KPL) was used to develop the plates before counting the foci on a BioSpot analyzer (Cellular Technology Limited). For neutralization experiments with luciferase expressing SARS-CoV-2, serum samples were diluted 3-fold starting at 1:50 and mixed with 85 PFU of each recombinant virus (wild-type and D614G). Vero E6 cells plated in clear-bottom black-walled 96-well plates (Corning) were inoculated with serum-virus mixtures, and cells were cultured at 37°C for 48 h. Subsequently, cells were lysed and luciferase activity was measured using the Nano-Glo Luciferase Assay System (Promega) according to the manufacturer's specifications.

### Hu-AdV5 neutralization assays {#sec4.4.5}

One day prior to Hu-AdV5-hACE2 transduction, serum samples were collected from mice immunized intramuscularly with ChAd-Control or ChAd-SARS-CoV-2-S. Sera were heat-inactivated and serially diluted prior to incubation with 10^2^ FFU of Hu-AdV5 for 1 h at 37°C. The virus-serum mixtures were added to HEK293 cell monolayers in 96-well plates and incubated for 1 h at 37°C. Cells were then overlaid with 1% (w/v) methylcellulose in MEM supplemented with 5% FBS. Plates were incubated at 37°C for 48 h before fixation with 2% PFA in PBS for 1 h at room temperature. Subsequently, plates were washed with PBS and incubated overnight at 4°C with biotinylated anti-HuAdV5-hexon antibody (2 μg/mL; Novus Biologicals NB600413) diluted in permeabilization buffer (PBS supplemented with 0.1% (w/v) saponin and 0.1% BSA). Plates were washed again and incubated with streptavidin-HRP (1:3000; Vector Laboratories SA-5004) in permeabilization buffer for 30 min at room temperature. After a final wash series, plates were developed using TrueBlue peroxidase substrate (KPL) and foci were counted on a BioSpot analyzer (Cellular Technology Limited).

### Protein expression and purification {#sec4.4.6}

Purified RNA from the 2019-nCoV/USA-WA1/2020 SARS-CoV-2 strain was reverse transcribed into cDNA and used as the template for recombinant gene cloning. A full-length SARS-CoV-2 NP was cloned into pET21a with a hexahistidine tag and recombinantly expressed using BL21(DE3)-RIL *E. coli* in Terrific Broth (bioWORLD). Following overnight induction with isopropyl β-d-1-thiogalactopyranoside (Goldbio) at 25°C, cells were lysed in 20 mM Tris-HCl pH 8.5, 1 M NaCl, 5 mM β-mercaptopethanol, and 5 mM imidazole for nickel-affinity purification. Following elution in the prior buffer supplemented with 500 mM imidazole, the protein was purified to homogeneity using size exclusion and, in some cases, cation exchange chromatography. SARS-CoV-2 RBD and S ectodomain (S1/S2 furin cleavage site was disrupted, double proline mutations were introduced into the S2 subunit, and foldon trimerization motif was incorporated) were cloned into pFM1.2 with a C-terminal hexahistidine or octahistidine tag, transiently transfected into Expi293F cells, and purified by cobalt-charged resin chromatography (G-Biosciences) as previously described ([@bib3]).

### ELISA {#sec4.4.7}

Purified antigens (S, RBD, or NP) were coated onto 96-well Maxisorp clear plates at 2 μg/mL in 50 mM Na~2~CO~3~pH 9.6 (70 μL) overnight at 4°C. Coating buffers were aspirated, and wells were blocked with 200 μL of 1X PBS + 0.05% Tween-20 + 1% BSA + 0.02% NaN~3~ (Blocking buffer, PBSTBA) either for 1 h at 37°C or overnight at 4°C. Heat-inactivated serum samples were diluted in PBSTBA in a separate 96-well polypropylene plate. The plates then were washed thrice with 1X PBS + 0.05% Tween-20 (PBST), followed by addition of 50 μL of respective serum dilutions. Sera were incubated in the blocked ELISA plates for at least 1 h at room temperature. The ELISA plates were again washed thrice in PBST, followed by addition of 50 μL of 1:2000 anti-mouse IgG-HRP (Southern Biotech Cat. \#1030-05) in PBST or 1:10000 of biotinylated anti-mouse IgG, anti-mouse IgM, or anti-mouse IgA in PBSTBA (SouthernBiotech). Plates were incubated at room temperature for 1 h, washed thrice in PBST, and then 1:5000 dilution of streptavidin-HRP (ThermoFisher) was added to wells. Following a 1 h incubation at room temperature, plates were washed thrice with PBST and 50 μL of 1-Step Ultra TMB-ELISA was added (ThermoFisher Cat. \#34028). Following a 12 to 15-min incubation, reactions were stopped with 50 μL of 2 M sulfuric acid. The absorbance of each well at 450 nm was read (Synergy H1) within 2 min of addition of sulfuric acid. Optical density (450 nm) measurements were determined using a microplate reader (Bio-Rad). The endpoint serum dilution was calculated with curve fit analysis of optical density (OD) values for serially diluted sera with a cut-off value set to three times the background signal.

### ELISpot assay {#sec4.4.8}

MultiScreen-HA filter 96-well plates (Millipore) plates were pre-coated with 3 μg/ml of SARS-CoV-2 S protein overnight at 4°C. After rinsing with PBST, plates were blocked for 4 h at 37°C with culture medium (RPMI, 10% FBS, penicillin-streptomycin, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 10 mM HEPES, and 50 mM β-mercaptoethanol). Single cell suspensions of splenocytes in culture medium were added to the S protein coated plates and incubated at 37°C and 5% humidified CO~2~ for 4 h. After washing with PBS and PBST, plates were incubated with biotinylated anti-IgG or anti-IgA (Southern Biotech) followed by incubation with streptavidin conjugated horseradish peroxidase (Jackson ImmunoResearch), each for 1 h at room temperature. After additional washes with PBS, 3-amino-9-ethylcarbazole (Sigma) substrate solution was added for spot development. The reaction was stopped by rinsing with water. Spots were counted using a Biospot plate reader (Cellular Technology).

### Measurement of viral burden {#sec4.4.9}

SARS-CoV-2 infected mice were euthanized using a ketamine and xylazine cocktail, and organs were collected. Tissues were weighed and homogenized with beads using a MagNA Lyser (Roche) in 1 mL of Dulbecco's Modified Eagle's Medium (DMEM) containing 2% fetal bovine serum (FBS). RNA was extracted from clarified tissue homogenates using MagMax mirVana Total RNA isolation kit (Thermo Scientific) and the KingFisher Flex extraction system (Thermo Scientific). SARS-CoV-2 RNA levels were measured by one-step quantitative reverse transcriptase PCR (qRT-PCR) TaqMan assay as described previously ([@bib27]). SARS-CoV-2 nucleocapsid (N) and Open Reading Frame 1a (ORF1a) specific primers and probe sets were used: (N: F Primer: ATGCTGCAATCGTGCTACAA; R primer: GACTGCCGCCTCTGCTC; probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/; ORF1a: F Primer: TTCAGTTGACTTCGCAGTGG; R primer: GGACGGGTTTGAGTTTTTCA; probe: /56-FAM/AACTAACAT/ZEN/CTTTGGCACTGTTT/3IABkFQ) (Integrated DNA Technologies). Viral RNA was expressed as (N) or (ORF1a) gene copy numbers per milligram on a log~10~ scale. For some samples, viral titer was determined by plaque assay on Vero E6 cells.

### Cytokine and chemokine mRNA measurements {#sec4.4.10}

RNA extracted from lung homogenates was DNase-treated and used to synthesize cDNA using the High-Capacity cDNA Reverse Transcription kit (Thermo Scientific) with the addition of RNase inhibitor according to the manufacturer's protocol. Cytokine and chemokine expression was determined using TaqMan Fast Universal PCR master mix (Thermo Scientific) with commercial primers/probe sets specific for *IFN-γ* (IDT: Mm.PT.58.41769240), *IL-6* (Mm.PT.58.10005566), *IL-1β* (Mm.PT.58.41616450), *CXCL10* (Mm.PT.58.43575827), *CCL2* (Mm.PT.58.42151692), *CCL5* (Mm.PT.58.43548565), *CXCL11* (Mm.PT.58.10773148.g), *IFN-β* (Mm.PT.58.30132453.g), and *IFNλ−2/3* (Thermo Scientific Mm04204156_gH) and results were normalized to *GAPDH* (Mm.PT.39a.1) levels. Fold change was determined using the 2^-ΔΔCt^ method comparing treated mice to naive controls.

### Plaque assay {#sec4.4.11}

Vero-Furin cells were seeded in 12-well plates one day prior to inoculation. Lung homogenates were serially diluted in DMEM supplemented with 2% FBS, HEPES, and penicillin-streptomycin and incubated on cells for 1 hr at 37°C. After 1 h incubation, cells were overlaid with 1% (w/v) methylcellulose in MEM with 2% FBS and incubated again at 37°C. At 3 dpi, overlays were removed, and plates were fixed with 4% PFA for 20 min at room temperature. After removal of PFA, plates were stained with 0.05% (w/v) crystal violet in 20% methanol for 10-20 min. Crystal violet was removed, and plates were rinsed with water or PBS. Plaques were counted manually to determine infectious virus titer.

### Peptide restimulation and intracellular cytokine staining {#sec4.4.12}

Splenocytes from intramuscularly vaccinated mice were incubated in culture with a pool of 253 overlapping 15-mer SARS-CoV-2 S peptides ([@bib23]) for 12 h at 37°C before a 4 h treatment with brefeldin A (BioLegend, 420601). Following blocking with FcγR antibody (BioLegend, clone 93), cells were stained on ice with CD45 BUV395 (BD BioSciences clone 30-F11); CD44 PE-Cy7, CD4 PE-Cy5, CD8b PreCP-Cy5.5, and CD19 APC-Cy7 (BioLegend clones, IM7, GK1.5, YTS156.7.7, and 6D5, respectively), and Fixable Aqua Dead Cell Stain (Invitrogen, L34966). Stained cells were fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBiosciences, 00-5523). Subsequently, intracellular staining was performed with anti-IFN-γ Alexa 647 (BD Biosciences, clone XMG1.2), anti-TNFα BV605 (BioLegend, clone MP6-XT22), and anti-GrB PE (Invitrogen, GRB04). Lungs from immunized mice were harvested and digested for 1 h at 37°C in digestion buffer consisting of RPMI media supplemented with (167 μg/ml) of Liberase DH (Sigma) and (100 μg/ml) of DNase I (Sigma). Lung cells were incubated at 37°C with the pool of 253 overlapping 15-mer SARS-CoV-2 S peptides described above in the presence of brefeldin A for 5 h at 37°C. Lung cells then were stained as described above except that CD4-BV421 (BioLegend clone GK1.5) replaced the CD4-PE-Cy5, no CD19 staining was included, and CD103-FITC and CD69-BV711 (BioLegend clones, 2E7, and, H1.2F3, respectively) were added. Analysis was performed on a BD LSRFortessa X-20 cytometer, using FlowJo X 10.0 software.

### Flow cytometry-based antigen characterization {#sec4.4.13}

HEK293T cells were seeded at 10^6^ cells/well in 6-well plates 24 h prior to transduction with ChAd-SARS-CoV-2-S (MOI of 5). After 20 h, cells were harvested, fixed and permeabilized using Foxp3 Transcription Factor Staining Buffer Set (Thermo Fisher), and stained for viral antigen after incubation with the following anti-SARS-CoV-2 neutralizing murine mAbs: SARS2-01, SARS2-02, SARS2-07, SARS2-11, SARS2-12, SARS2-16, SARS2-18, SARS2-20, SARS2-21, SARS2-22, SARS2-23, SARS2-29, SARS2-31, SARS2-32, SARS2-34, SARS2-38, SARS2-39, SARS2-50, SARS2-55, SARS2-58, SARS2-66, and SARS2-71 (L.A.V. and M.S.D., unpublished data). H77.39 ([@bib51]), an isotype-matched anti-HCV E2 mAb was used as a negative control. Cells were washed, incubated with Alexa Fluor 647 conjugated goat anti-mouse IgG (Thermo Fisher), and analyzed by flow cytometry using a MACSQuant Analyzer 10 (Miltenyi Biotec). The percentage of cells positive for a given mAb was compared with cells stained with a saturating amount of an oligoclonal mixture of anti-SARS-CoV-2 mAbs.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical significance was assigned when *P value*s were \< 0.05 using Prism Version 8 (GraphPad). Tests, number of animals (n), median values, and statistical comparison groups are indicated in the Figure legends. Analysis of anti-S, anti-RBD, neutralization titers, and ELISPOT values in mice after vaccination was performed using a Mann-Whitney test. Differences in viral titers or chemokine and cytokine levels after SARS-CoV-2 infection of immunized mice were determined using a Mann-Whitney test. Anti-nucleoprotein antibody levels were compared using a paired t test.
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